Stiefel launches Sorilux foam

LONDON — Stiefel, a GlaxoSmithKline company, announced the availability of Sorilux foam by prescription.

The product is a topical treatment of plaque psoriasis in patients ages 18 years or older. Sorilux foam utilizes VersaFoam technology. VersaFoam-AEF (aqueous-based emulsion formulation) is free of ethanol, preservatives, parabens and fragrance, Stiefel said. The company also noted the foam is the only vitamin D3 analog treatment in a topical foam formulation.

Additional details may be found here.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.